A drug-delivery vehicle combining the targeting and thermal ablation of HER2+ breast-cancer cells with triggered drug release

Angew Chem Int Ed Engl. 2013 Apr 8;52(15):4141-6. doi: 10.1002/anie.201209804. Epub 2013 Mar 11.

Abstract

Multi-targeted drug delivery vehicles encapsulating doxorubicin within a pH-sensitive matrix, embedded with gold nanoparticles, and decorated on the surface with Herceptin®-polyethylene glycol conjugates were synthesized for enhanced specific binding and tumoricidal efficacy in HER2 overexpressing SK-BR-3 cells. We demonstrated that multiple modes of targeting were complementary and have potential for use as a cancer therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Dose-Response Relationship, Drug
  • Doxorubicin / pharmacology*
  • Drug Carriers / chemical synthesis
  • Drug Carriers / chemistry*
  • Drug Delivery Systems*
  • Drug Screening Assays, Antitumor
  • Female
  • Humans
  • Hydrogen-Ion Concentration
  • MCF-7 Cells
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / metabolism
  • Structure-Activity Relationship
  • Temperature*

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Doxorubicin
  • ERBB2 protein, human
  • Receptor, ErbB-2